Potassium Supplements Interactions

Simultaneous administration can produce severe hyperkalemia.

Source: NLP:potassium bicarbonate

Concomitant use can produce severe hyperkalemia. Avoid concomitant use.

Source: NLP:potassium chloride

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic

Potassium supplements can increase the risk of hyperkalemia. Frequent monitoring of serum potassium is recommended if concomitant use is indicated.

Source: NLP:amlodipine besylate and benazepril hydrochloride

Co-administration may result in hyperkalemia. Monitor serum potassium levels in such patients.

Source: NLP:candesartan

Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.

Source: NLP:candesartan cilexetil

May lead to significant increases in serum potassium.

Source: NLP:enalapril

Can increase risk of hyperkalemia when combined with fosinopril. Should be used with caution and serum potassium monitored frequently.

Source: NLP:fosinopril

Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.

Source: NLP:fosinopirl sodium

Coadministration with drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe. Monitor serum potassium in such patients.

Source: NLP:irbesartan

May lead to increases in serum potassium. Monitoring of serum potassium is advisable.

Source: NLP:olmesartan medoxomil

Increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other risk factors. Avoid use if possible.

Source: NLP:sodium chloride and potassium chloride

Concurrent use may result in hyperkalemia and cardiac arrhythmias or cardiac arrest.

Source: NLP:potassium iodide

May cause hyperkalemia when used with potassium phosphate. Periodic serum potassium monitoring required.

Source: NLP:potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Source: NLP:potassium phosphates

Increases risk of hyperkalemia. Frequent monitoring of serum potassium recommended if concomitant use indicated.

Source: NLP:ramipril

Avoid concomitant use due to increased risk of severe and potentially fatal hyperkalemia. If unavoidable, closely monitor serum potassium concentrations.

Source: NLP:dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride

May cause hyperkalemia. Periodic serum potassium level determinations recommended.

Source: NLP:dibasic sodium phosphate, monobasic potassium phosphate and monobasic sodium phosphate

Concomitant administration may lead to severe hyperkalemia. Discontinue potassium supplementation in heart failure patients starting spironolactone.

Source: NLP:spironolactone

Concomitant administration may lead to severe hyperkalemia.

Source: NLP:spironolactone and hydrochlorothiazide

May promote serum potassium accumulation and result in hyperkalemia with triamterene, especially in patients with renal insufficiency.

Source: NLP:triamterene and hydrochlorothiazide

May lead to increases in serum potassium and in heart failure patients to increases in serum creatinine when used with valsartan.

Source: NLP:valsartan and hydrochlorothiazide

ECG changes and hypokalemia from non-potassium-sparing diuretics can be worsened by beta-agonists. Use with caution, especially at higher albuterol doses.

Source: NLP:albuterol sulfate

May lead to increases in serum potassium when combined with valsartan. Monitor serum potassium levels.

Source: NLP:amlodipine and valsartan

Loop or thiazide diuretics can worsen ECG changes and hypokalemia. Caution advised in co-administration.

Source: NLP:arformoterol tartrate inhalation solution

Concomitant use may affect potassium levels. Monitor potassium periodically.

Source: NLP:benazepril hydrochloride and hydrochlorothiazide

Enalapril attenuates potassium loss caused by thiazide diuretics; combined use may increase serum potassium. Monitor potassium levels.

Source: NLP:enalapril maleate

May lead to significant increases in serum potassium when used with enalaprilat. Use with caution and monitor serum potassium frequently.

Source: NLP:enalaprilat

Electrocardiographic changes and hypokalemia may worsen with concomitant beta-agonists.

Source: NLP:fluticasone propionate and salmeterol

ECG changes and hypokalemia from these diuretics can be worsened by formoterol, especially at higher doses. Caution advised.

Source: NLP:formoterol fumarate

ECG changes and hypokalemia from these diuretics can be worsened by formoterol, especially at higher doses. Caution advised.

Source: NLP:formoterol fumarate dihydrate

May increase risk of hyperkalemia with fosinopril sodium and hydrochlorothiazide; concomitant use requires caution and frequent serum potassium monitoring.

Source: NLP:fosinopril sodium and hydrochlorothiazide

Coadministration with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.

Source: NLP:losartan potassium

Concomitant use with moexipril can increase risk of hyperkalemia. Should be given with caution and patient's serum potassium should be monitored.

Source: NLP:moexipril hydrochloride

Coadministration may result in hyperkalemia. Monitor serum potassium levels.

Source: NLP:olmesartan medoxomil and hydrochlorothiazide

Concurrent use may potentiate the potassium-wasting action of diuretics, requiring monitoring of potassium levels before and during treatment.

Source: NLP:phentermine and topiramate extended-release

May lead to increased serum potassium levels. Monitor potassium during concomitant use.

Source: NLP:sacubitril and valsartan

Non-potassium sparing diuretics may result in ECG changes and hypokalemia that can be worsened by olodaterol. Caution advised in co-administration.

Source: NLP:tiotropium bromide and olodaterol

Concomitant use increases hyperkalemia risk by approximately 1-2%. Serum potassium levels should be monitored.

Source: NLP:tolvaptan

Can increase risk of hyperkalemia when used concomitantly with trandolapril. Use with caution and monitor serum potassium.

Source: NLP:trandolapril